

Patent Claims

1. A transdermal therapeutic system with a content of candesartan or one of its pharmaceutically suitable esters or salts.

2. A transdermal therapeutic system according to claim 1, characterized by candesartan as active ingredient.

3. A transdermal therapeutic system according to claim 1, characterized by candesartan cilexetil as active ingredient.

4. A transdermal therapeutic system according to claim 1, characterized by the ammonium and/or alkali metal salts of candesartan as active ingredient.

5. A transdermal therapeutic system according to any of the preceding claims, characterized by candesartan or one of its pharmaceutically acceptable esters or salts as active ingredient in combination with other active ingredients.

6. A transdermal therapeutic system according to claim 5, characterized by at least one other active ingredient which enhances the effect of candesartan.

TEST AVAILABLE COPY

7. A transdermal therapeutic system according to claim 5 or 6, characterized by diuretics and/or Ca channel blockers as other active ingredients.

8. A transdermal therapeutic system according to any of the preceding claims in the form of a plaster with an impermeable covering layer and a detachable protective layer,

in particular in the form of a matrix system or of a membrane system.

9. A transdermal therapeutic system according to claim 8, characterized by a covering layer based on polyester, polypropylene, polyurethane or polyethylene, where appropriate in each case metalized or pigmented.

10. A transdermal therapeutic system according to claim 8, characterized by a detachable protective layer based on polyester, polypropylene, polysiloxane, polyacrylate, ethylene/vinyl acetate, polyurethane, polyisobutene or paper with silicone and/or polyethylene coating.

11. A transdermal therapeutic system according to claim 8, 9 or 10, characterized in that it is a matrix system with

- an impermeable covering layer,
- one or more active ingredient-containing contact adhesive matrix layer(s) or one or more active ingredient-containing matrix layer(s) coated with a contact adhesive,
- a detachable protective layer and
- candesartan or one of its pharmaceutically acceptable esters or salts as active ingredient.

12. A transdermal therapeutic system according to claim 11, characterized by a matrix layer based on polyacrylate, silicone, polyisobutylene, rubber, rubber-like synthetic homo-, co- or block polymers, butyl rubber, styrene/isoprene

BEST AVAILABLE COPY

copolymer, polyurethanes, copolymers of ethylene, polysiloxanes or styrene/butadiene copolymer.

13. A transdermal therapeutic system according to claim 8, 9 or 10, characterized in that it is a membrane system with

- an impermeable covering layer,
- an active ingredient-containing reservoir or an active ingredient-containing reservoir layer,
- a microporous or semipermeable membrane,
- an optional contact adhesive layer,
- candesartan or one of its pharmaceutically acceptable esters or salts as active ingredient.

14. A transdermal therapeutic system according to claim 13, characterized by a membrane based on an inert polymer, in particular polypropylene, polyvinyl acetate, polyamide, ethylene/vinyl acetate copolymer or silicone.

BEST AVAILABLE COPY

15. A transdermal therapeutic system according to any of the preceding claims, characterized by a permeation promoter, in particular monohydric and/or polyhydric aliphatic, cycloaliphatic and/or aromatic-aliphatic alcohols each with up to 8 C atoms, and/or polyethylene glycol; alcohol/water mixtures; saturated and/or unsaturated fatty alcohols each with 8-18 C atoms; terpenes; mixtures of terpenes and ethanol and/or propylene glycol; tea tree oil; saturated and/or unsaturated cyclic ketones; alkyl methyl sulfoxides; saturated and/or unsaturated fatty acids each with 8-18 C

atoms; the esters and salts thereof; natural vitamin E; synthetic vitamin E and/or vitamin E derivatives; sorbitan fatty acid esters and ethoxylated sorbitan fatty acid esters; Azone (laurocapram); Azone mixed with alcohols; urea; 1-alkylpyrrolidone; block copolymers of polyethylene glycol and dimethylsiloxane with cationic groups at one end; folate-polyethylene glycol liposome, proliposome; polyoxyethylene 10 stearyl ether; mixture of polyoxyethylene 10 stearyl ether and glyceryl dilaurate; dodecyl 2-(N,N-dimethylamino)propanoate and/or dodecyl 2-(N,N-dimethylamino)propionate; N-acetylproline esters with more than 8 C atoms; nonionic surfactants, esters of polyoxyethylene; ethosome (phospholipid vesicle); dimethyl(arylimino)sulfurane; mixture of oleic acid analogs and propylene glycol; mixture of padimate O, octyl salicylate, octyl methoxycinnamate and laurocapram and/or mixtures of all these components.

add 12/

BEST AVAILABLE COPY

*2nd
B5*

✓B5